ANDA 209834, held by Chartwell Rx. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 209834 (Sodium Nitroprusside), held by Chartwell Rx, was first approved by FDA on Jun 26, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Nitroprusside25MG/ML ยท injectable;injection | Sodium Nitroprusside | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters